Search Results

You are looking at 31 - 40 of 176 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Afatinib and Nivolumab as Treatment of Platinum- and Cetuximab-Refractory Recurrent/Metastatic Squamous Cell Carcinoma

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the

Full access

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in

Full access

Jaffer A. Ajani

predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab . Ann Oncol 2008 ; 19 : 508 – 515 . 14. Lievre A Bachet JB Le Corre D . KRAS mutation status is predictive of response

Full access

Al B. Benson III, Alan P. Venook, Lynette Cederquist, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Peter C. Enzinger, Alessandro Fichera, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Christina S. Wu, Kristina M. Gregory, and Deborah Freedman-Cass

, oxaliplatin, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, ramucirumab, regorafenib, trifluridine-tipiracil, pembrolizumab, and nivolumab. 7 – 48 The putative mechanisms of action of these agents are varied and include interference with DNA

Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

of conversing unresectable disease to resectable disease in combination with anti-epidermal growth factor receptor (EGFR) inhibitors. 32 , 33 For instance, in the CELIM phase II trial, patients were randomized to receive cetuximab with either FOLFOX6

Full access

Diane Reidy and Leonard Saltz

) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): 172s . Abstract 4036 . 13. Saltz L Rubin M Hochster H . Cetuximab plus

Full access

Armstrong, MD • 919-668-8108 ClinicalTrials.gov Identifier: NCT00887640 Weekly Nanoparticle Albumin-Bound Paclitaxel Plus Weekly Cetuximab Plus Radiation Therapy in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma Principal

Full access

Rona Yaeger and Leonard Saltz

the therapeutic intervention used. In a combined analysis of the CRYSTAL and OPUS trials, which explored the addition of cetuximab to front-line chemotherapy for metastatic colorectal cancer, a substantially diminished overall survival was seen for